Appetite and the weight you carry
Which substances have helped people lose weight?
Hunger can linger after you finish eating. Tirzepatide, semaglutide, AOD-9604 and MOTS-c are discussed for weight, but their studies show very different results.
Tirzepatide: What changed in people?
GIP and GLP-1 are hormones from the gut; tirzepatide copies their actions on sugar. Human trials checked weight loss and unwanted effects.
Look at the weight trials →
Semaglutide: Was there help beyond weight?
The gut hormone GLP-1 helps control sugar and appetite; semaglutide copies this hormone. Separate trials examined serious trouble affecting kidneys and hearts.
Check the other health findings →
AOD-9604: Did the mouse findings hold up?
Mice had fat changes after receiving a growth-hormone piece. The human trials that followed did not establish the hoped-for benefit in weight.
Find out what failed in people →
MOTS-c: What remains untested in people?
Mice given MOTS-c moved better. Measuring natural human blood levels did not test the benefit or harm of extra treatment.
Understand the untreated blood study →What does this guide tell you about weight?
Hunger and extra weight can make daily life harder, but a treatment claim still needs proof. The name Metabolic & Weight research peptides puts weight studies beside research on using food for energy. Your body links small parts called amino acids to form peptides and proteins. Some peptides have approved medical uses, while others still lack proof that human treatment helps.
The word peptide covers all four substances, but each has a different record of benefit.
Large trials treated people with tirzepatide or semaglutide, checking weight loss and unwanted effects. Growth hormone helps bones and other tissues grow; researchers used part of that hormone to make AOD-9604. The mouse fat findings looked promising, but people didn't get the useful weight loss hoped for. Most MOTS-c treatment tests used laboratory cells or mice, leaving the effect of human treatment unknown.
You can't judge AOD-9604 by tirzepatide's weight results, or MOTS-c by semaglutide's safety results. These findings may be useful during a discussion of your health with a doctor. We don't sell substances or give instructions for treatment.
Why did the weight results differ?
The direct drug comparison tested only tirzepatide and semaglutide, leaving the other substances outside that trial. GIP and GLP-1 come from the gut around meals; the messages carried by these hormones affect blood sugar. Both hormone actions are copied by tirzepatide, while semaglutide copies GLP-1. The direct trial found a larger average fall in weight among those receiving tirzepatide [1]. That doesn't show that every drug copying both hormones would do better.
AOD-9604 was designed to affect fat without the growth effects of whole growth hormone. In overweight mice, treatment increased fat burning and reduced weight [15][16]. Human tests used placebo for comparison; the tested substance was absent from the placebo treatment. Unwanted effects were much alike, but the expected useful weight loss wasn't shown [14].
A mouse weight finding leaves the answer about your own weight change unproved.
Your body makes MOTS-c naturally. Experiments suggested that MOTS-c affected sugar entering mouse muscles and helped cells respond when energy was scarce [17][19][21]. A small study measured people's natural blood levels before following their health [18]. Nobody in that study received extra MOTS-c.
Can a research peptide also be an approved medicine?
A peptide usually contains fewer amino acids than a protein does. Research peptide is a term that says little about whether a substance has passed approval checks. Those words may describe substances being tested in a laboratory. People sometimes use the same term when talking about approved medicines.
The name alone cannot settle your safety question.
Tirzepatide and semaglutide were changed so your body removes the medicines more slowly. Both have approved prescription uses, backed by human trials and safety reviews [1][2][4][8][9][10][11]. Approval still can't promise that a medicine will help every person.
AOD-9604 underwent human testing without becoming an approved weight treatment. These papers failed to establish benefit from giving people AOD-9604 or MOTS-c. A research product may contain germs, unwanted chemicals or contents that differ from the name on the package. Calling a product a peptide doesn't show how well the product was made or whether a doctor oversees its use.
How can you tell what a study really showed?
A short study with few people can miss harm or benefit that takes years to appear. Choosing treatments by chance reduces the risk that groups differ before any treatment begins. A study that only watches people may find a connection without establishing why their health changed. Mouse and cell tests cannot prove that treating people helps.
First ask what the researchers gave each group.
Tirzepatide was compared with semaglutide or with placebo containing no tested medicine [1][4][5]. Semaglutide trials compared weight, heart trouble and kidney problems against placebo [8][9][10]. AOD-9604 papers covered human side effects, animal fat changes and how the substance broke down, without proving useful human weight loss [13][14][15][16]. MOTS-c experiments treated mostly animals or cells. The human study measured natural blood levels without giving extra MOTS-c [17][18][19][20][21].
Your risks depend on the particular substance, and brief tests can't establish years of safety. The different study findings can help you bring these questions to your doctor.